Lucid Diligence Brief: Lilly to acquire Ajax Therapeutics
Lucid Diligence Brief: Lilly to acquire Ajax Therapeutics Professional…
Lucid Diligence Brief: Cantargia nadunolimab in MDS and AML
Lucid Diligence Brief: Cantargia nadunolimab in MDS and AML Professional…
Lucid Diligence Brief: MSD to acquire Terns
Lucid Diligence Brief: MSD to acquire Terns Professional audiences only. Not…
Lucid Diligence Brief: Disc Medicine bitopertin FDA CRL
Lucid Diligence Brief: Disc Medicine bitopertin FDA CRL Professional audiences…
Healthcare and Pharma Industry Trends H2 2025: From Innovation to Execution
An in-depth analysis of pharma and healthcare industry trends in H2 2025,…
Lucid Diligence Brief: Galecto acquires Damora Therapeutics
Lucid Diligence Brief: Galecto acquires Damora Therapeutics Professional…
Lucid Diligence Brief: Electra Therapeutics $183M Series C
Lucid Diligence Brief: Electra Therapeutics $183M Series C Professional…
Hematology Today: CAR-T, Gene Therapy and Radioconjugates (Oct 6–13, 2025)
This week’s hematology update highlights groundbreaking CAR-T and gene therapy…
Women's Health Weekly News - August 20th 2025
Women’s Health Breakthroughs: Migraine, Fibromyalgia, Postpartum Depression and…
Rare Diseases Weekly News - August 14th 2025
🧬 This Week in Rare Diseases: FDA Approvals, Global Partnerships, Breakthrough…
Rare Diseases Weekly News - July 31st 2025
🧬 This Week in Rare Diseases: FDA Leadership, Gene Therapy Safety, New Drug…
EHA 2025 Preview: Key Hematology Highlights to Watch
EHA at a glance Join LucidQuest for a concise EHA 2025 preview, focusing on…